Chief Technical Officer
George Avgerinos served for 23 years as a senior technical operations executive at Abbott/Abbvie where he contributed to the founding and management of the former BASF (Abbott /Abbvie) Oncology and Immunology Research Foundation. He retired from Abbvie in 2013 as Divisional VP for Global Biologics Operations with responsibility for the Humira Franchise.
Dr. Avgerinos started his career in technical operations with the founders of Biogen and concurrently developed a curriculum and mentored students as Adjunct Associate Professor of Chemical and Biochemical Engineering at Tufts. He remains active supporting the establishment and operating strategy for multiple start-up ventures including TG Therapeutics, Checkpoint Therapeutics, Caelum, Mustang Bio, Coronado Biosciences, Fortress Biotechnology, and most recently Flame Biosciences.
Dr. Avgerinos received a B.A. in Biophysics from the University of Connecticut and Ph.D. in Chemical and Biochemical Engineering from the Massachusetts Institute of Technology.